Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEMDNASDAQ:QNRXOTCMKTS:SIGYNYSEAMERICAN:VTAK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEMDAethlon Medical$0.36-1.5%$0.37$0.24▼$1.06$5.80M1.932.27 million shs337,291 shsQNRXQuoin Pharmaceuticals$8.85-1.7%$7.26$5.01▼$54.95$5.20M1.44136,006 shs2,990 shsSIGYSigyn Therapeutics$2.49$3.67$2.49▼$5.75$4.00M-1.03466 shsN/AVTAKCatheter Precision$0.20+0.4%$0.28$0.16▼$8.40$1.79M-0.341.16 million shs450,449 shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEMDAethlon Medical+4.37%-1.22%-4.09%-20.60%-10.88%QNRXQuoin Pharmaceuticals+1.01%-3.95%+42.86%-14.34%-64.32%SIGYSigyn Therapeutics0.00%0.00%-29.46%-39.27%-52.57%VTAKCatheter Precision+2.55%+7.65%-27.34%-36.81%-95.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEMDAethlon Medical2.9293 of 5 stars3.55.00.00.02.00.01.3QNRXQuoin Pharmaceuticals0.2515 of 5 stars0.03.00.00.00.80.00.6SIGYSigyn TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AVTAKCatheter Precision0.4033 of 5 stars0.03.00.00.00.60.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEMDAethlon Medical 3.00Buy$7.001,844.44% UpsideQNRXQuoin Pharmaceuticals 0.00N/AN/AN/ASIGYSigyn Therapeutics 0.00N/AN/AN/AVTAKCatheter Precision 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VTAK, AEMD, SIGY, and QNRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/10/2025AEMDAethlon MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEMDAethlon Medical$570K10.14N/AN/A$2.19 per share0.16QNRXQuoin PharmaceuticalsN/AN/AN/AN/A$5.74 per shareN/ASIGYSigyn TherapeuticsN/AN/AN/AN/A($2.80) per shareN/AVTAKCatheter Precision$440K4.06N/AN/A$30.16 per share0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEMDAethlon Medical-$12.21M-$1.58N/AN/AN/AN/A-153.96%-109.13%6/26/2025 (Estimated)QNRXQuoin Pharmaceuticals-$8.69M-$48.81N/AN/AN/AN/A-125.60%-64.77%8/14/2025 (Estimated)SIGYSigyn Therapeutics-$4.15M-$4.57N/A∞N/AN/AN/A-1,147.41%N/AVTAKCatheter Precision-$70.57MN/A0.00N/AN/A-2,928.32%-69.90%-41.82%8/13/2025 (Estimated)Latest VTAK, AEMD, SIGY, and QNRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/26/2025Q4 2025AEMDAethlon Medical-$0.13N/AN/AN/AN/AN/A5/20/2025Q1 2025SIGYSigyn TherapeuticsN/A-$0.42N/A-$0.42N/AN/A5/13/2025Q1 2025QNRXQuoin Pharmaceuticals-$3.85-$6.50-$2.65-$6.50N/AN/A4/15/2025Q4 2024SIGYSigyn TherapeuticsN/A-$2.51N/A-$2.51N/AN/A3/13/2025Q4 2024QNRXQuoin Pharmaceuticals-$17.50-$12.25+$5.25-$0.35N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEMDAethlon MedicalN/AN/AN/AN/AN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/AN/ASIGYSigyn TherapeuticsN/AN/AN/AN/AN/AVTAKCatheter PrecisionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEMDAethlon MedicalN/A2.802.80QNRXQuoin PharmaceuticalsN/A3.023.02SIGYSigyn TherapeuticsN/A0.060.05VTAKCatheter Precision0.120.660.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEMDAethlon Medical1.99%QNRXQuoin Pharmaceuticals8.63%SIGYSigyn Therapeutics10.01%VTAKCatheter Precision20.34%Insider OwnershipCompanyInsider OwnershipAEMDAethlon Medical1.20%QNRXQuoin Pharmaceuticals3.70%SIGYSigyn Therapeutics78.46%VTAKCatheter Precision1.35%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEMDAethlon Medical1016.06 million14.30 millionNo DataQNRXQuoin Pharmaceuticals4588,0004.86 millionNot OptionableSIGYSigyn Therapeutics51.61 million346,000Not OptionableVTAKCatheter Precision148.84 million8.72 millionN/AVTAK, AEMD, SIGY, and QNRX HeadlinesRecent News About These CompaniesCatheter Precision, Inc. Receives CE Mark Approval for LockeT, Expanding Market Opportunities in EuropeMay 27, 2025 | quiverquant.comCatheter Precision, Inc. Receives CE Mark for LockeTMay 27, 2025 | globenewswire.comCatheter Precision Enters Market Offering AgreementMay 19, 2025 | tipranks.comCatheter Precision, Inc. Announces First Quarter 2025 Update and Financial ResultsMay 15, 2025 | finance.yahoo.comCatheter Precision, Inc. Announces $1.5 Million Private Placement Equity Financing and ...May 12, 2025 | gurufocus.comCatheter Precision, Inc. Announces $1.5 Million Private Placement Equity Financing and Potential Strategic AllianceMay 12, 2025 | globenewswire.comCatheter Precision Finalizes Strategic Cardiac AcquisitionMay 8, 2025 | tipranks.comCatheter Precision, Inc. Completes Acquisition of Cardionomic Heart Failure AssetsMay 6, 2025 | finance.yahoo.comNew Clinical Data Presented about VIVO at the 46th Annual Heart Rhythm Association ConferenceMay 1, 2025 | finance.yahoo.comCatheter Precision to Attend and Participate in the 46th Heart Rhythm SocietyApril 24, 2025 | finance.yahoo.comCatheter Precision Acquires Late-Stage Heart Failure Therapy AssetsApril 23, 2025 | theglobeandmail.comCatheter Precision to Acquire Assets in Development for Late-Stage Treatment for Acute Decompensated Heart FailureApril 23, 2025 | finance.yahoo.comCatheter Precision, Inc. Announces Receipt of Audit Opinion with Going Concern DoubtApril 17, 2025 | quiverquant.comCatheter Precision Makes NYSE American Section 610(b) Public AnnouncementApril 17, 2025 | globenewswire.comCatheter Precision, Inc. Receives Notice of First Patent Allowance in the US for LockeT Product LineApril 14, 2025 | markets.businessinsider.comCatheter Precision, Inc. Announces Fourth Quarter and Full Year 2024 Update and Financial ResultsMarch 28, 2025 | globenewswire.comCatheter Precision to Participate in and Share Data at Upcoming Industry ConferencesMarch 26, 2025 | markets.businessinsider.comFDA clears Imperative Care’s Symphony 16F 82cm catheterMarch 24, 2025 | massdevice.comCatheter Precision to Attend and Participate in the Western Atrial Fibrillation SymposiumFebruary 27, 2025 | markets.businessinsider.comCatheter Precision to attend, participate in ISLAAFebruary 11, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVTAK, AEMD, SIGY, and QNRX Company DescriptionsAethlon Medical NASDAQ:AEMD$0.36 -0.01 (-1.48%) As of 02:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation. The company was incorporated in 1999 and is based in San Diego, California.Quoin Pharmaceuticals NASDAQ:QNRX$8.85 -0.15 (-1.67%) As of 02:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.Sigyn Therapeutics OTCMKTS:SIGY$2.49 0.00 (0.00%) As of 06/4/2025Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.Catheter Precision NYSEAMERICAN:VTAK$0.20 +0.00 (+0.40%) As of 02:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Catheter Precision, Inc. designs, manufactures, and sells medical technologies for the field of cardiac electrophysiology (EP) in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device that temporarily secure sutures and aid clinicians in locating and removing sutures; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company sells it products through distribution partners, independent sales agents, and direct employees. Catheter Precision, Inc. is based in Fort Mill, South Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Guidewire Rockets Higher: A Move Above $300 Is Probable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
